Prostate cancer, version 1.2021: Featured updates to the nccn guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D'Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George NettoDavid F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass

Research output: Contribution to journalArticlepeer-review

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)134-143
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number2
DOIs
StatePublished - Feb 2 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Prostate cancer, version 1.2021: Featured updates to the nccn guidelines'. Together they form a unique fingerprint.

Cite this